Education
About Us
Working with TipRanks
Follow Us
Nuwellis (NUWE)
NASDAQ:NUWE
NUWE Stock Chart & Stats
$2.41
-$0.08(-7.15%)
At close: 4:00 PM EST
$2.41
-$0.08(-7.15%)
Day’s Range― - ―
52-Week Range$2.02 - $70.14
Previous CloseN/A
Volume102.02K
Average Volume (3M)289.18K
Market Cap
$2.43M
Enterprise Value-$2.10M
Total Cash (Recent Filing)$3.09M
Total Debt (Recent Filing)$383.00K
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Mar 03, 2026EPS Estimate
-1.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding902,665
10 Day Avg. Volume82,161
30 Day Avg. Volume289,177
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)9.48
Price to Sales (P/S)7.08
P/FCF Ratio-6.41
Enterprise Value/Market Cap-0.87
Enterprise Value/Revenue-0.26
Enterprise Value/Gross Profit-0.42
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$3.90Price Target Upside61.83% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pediatric RevenueStrong growth in Pediatric revenue, up 28% year-over-year, following the addition of three new accounts during the quarter.
ReimbursementThe CMS will reassign the Aquadex ultrafiltration code to increase reimbursement rates, which should provide a profitable reimbursement pathway and expand the number of patients who can receive the therapy.
Revenue GrowthThe slight revenue beat in 2Q24 is a positive sign that the company is expanding its presence within the medical system and driving increased utilization of consumables.
Bears Say
Cash FlowEven with the higher reimbursement rates, the company is not expected to operate on a positive cash flow basis through at least 2026.
Pediatric UtilizationThe y/y decline in the quarter in pediatric utilization gives some concern.
ProfitabilityThe timeline towards profitability remains unclear, likely requiring additional dilutive capital raises, which dampens the investment outlook.
Nuwellis News
NUWE FAQ
What was Nuwellis’s price range in the past 12 months?
Nuwellis lowest stock price was $2.02 and its highest was $70.14 in the past 12 months.
What is Nuwellis’s market cap?
Nuwellis’s market cap is $2.43M.
When is Nuwellis’s upcoming earnings report date?
Nuwellis’s upcoming earnings report date is Mar 03, 2026 which is in 93 days.
How were Nuwellis’s earnings last quarter?
Nuwellis released its earnings results on Nov 12, 2025. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of N/A by $0.56.
Is Nuwellis overvalued?
According to Wall Street analysts Nuwellis’s price is currently Undervalued.
Does Nuwellis pay dividends?
Nuwellis does not currently pay dividends.
What is Nuwellis’s EPS estimate?
Nuwellis’s EPS estimate is -1.56.
How many shares outstanding does Nuwellis have?
Nuwellis has 902,665 shares outstanding.
What happened to Nuwellis’s price movement after its last earnings report?
Nuwellis reported an EPS of $0.56 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.957%.
Which hedge fund is a major shareholder of Nuwellis?
Currently, no hedge funds are holding shares in NUWE
Company Description
Nuwellis
Nuwellis (NUWE) is a medical technology company specializing in innovative solutions for fluid management and treatment of patients with chronic conditions. The company operates primarily in the healthcare sector, focusing on developing advanced medical devices and therapies aimed at improving patient outcomes in conditions related to fluid overload, such as heart failure and kidney disease. Nuwellis's core products include its proprietary devices designed to assist in the safe and effective removal of excess fluid from patients, thereby enhancing their quality of life and reducing hospital readmissions.
NUWE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Negative
The earnings call highlights several strategic initiatives and resolutions, such as pediatric revenue growth and successful transition plans, which are promising for future growth. However, the current financial performance is challenged by a significant revenue decline, reduced gross margins, and increased operating losses. While there are positive steps being taken, the immediate financial indicators present a negative outlook.View all NUWE earnings summariesNUWE Stock 12 Month Forecast
Average Price Target
$3.90
▲(61.83% Upside)
Technical Analysis
Aethlon Medical
―
PAVmed
―
Catheter Precision
―
Bone Biologics
―
Heart Test Laboratories, Inc.
―
Ownership Overview
66.31% Insiders
0.05% Mutual Funds
4.34% Other Institutional Investors
29.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---